In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Cancer and Vascular Toxicity

09 Nov 2020
Gulati

Geeta Gulati

Listen to Professor Sofie Gevaert and Dr Geeta Gulati in this interview which focuses on:

  • Baesline cardiovascular risk assessmet in patients planned for cancer treatment
  • Prevention and screening for CAD

References


Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1920

 

Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC) https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1957

 

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
About the ESC
Press and Media
Information
Follow us

         

 Need help?

 Help centre
 Contact us

© 2024 European Society of Cardiology. All rights reserved.